A Gut Feeling for Metformin
- PMID: 30517894
- DOI: 10.1016/j.cmet.2018.11.012
A Gut Feeling for Metformin
Abstract
Metformin is a first-line glucose-lowering agent in patients with type 2 diabetes (T2D). Recently in Nature Medicine, Sun et al. (2018) reported that short-term metformin therapy decreases gut Bacteroides fragilis, consequently increasing glycoursodexoycholic acid (GUDCA) levels in humans. As an antagonist of FXR, GUDCA may carry therapeutic potential in the treatment of T2D.
Copyright © 2018 Elsevier Inc. All rights reserved.
Comment on
-
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin.Nat Med. 2018 Dec;24(12):1919-1929. doi: 10.1038/s41591-018-0222-4. Epub 2018 Nov 5. Nat Med. 2018. PMID: 30397356 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
